August 20, Blueprint Medicines is working with The Life Raft Group and GIST Support International to host a webinar providing a data update from the registration-enabling NAVIGATOR trial of the investigational treatment avapritinib in patients with PDGFRA Exon 18 mutant GIST and fourth-line GIST.
Learn the basics of our new ListServ replacement launching on October 15th, GIST Chat.
In honor of Rare Disease in the Soft Tissue Day, OncLive is hosting webinars on March 5 and March 6 at 12pm EST about soft tissue sarcoma. GIST is a soft tissue sarcoma. [...]
In honor of Rare Disease in the Soft Tissue Day, OncLive is hosting webinars on March 5 and March 6 at 12pm EST about soft tissue sarcoma. GIST is a soft tissue sarcoma. [...]
Jim Hughes outlines the importance of patients/caregivers researching their cancer in order to best advocate for themselves.
Dr. Candace Haddox of Dana-Farber Cancer Institute will offer invaluable insights into the world of clinical trials in honor of International Clinical Trials Awareness Day as well as discussing trials with GIST Advocate Kandee Evans
Dr. Herbert Loong will summarize abstracts and presentations that were presented during the American Society of Clinical Oncology (ASCO) which is an important conference in the oncology community where new scientific research updates are shared.
July 13th, GIST Awareness Day, is a time when GIST experts, patients, and caregivers come together to educate the public about this disease and advocate for finding a cure. The Life Raft Group invites [...]
Dr. Weiss of Washington University School of Medicine in St. Louis will provide an overview of GIST treatments and side effects as well as home management for each type of symptom.
Dr. Kim of Mount Sinai Medical Center will describe various locoregional therapies and their appropriate uses, as well as the role of locoregional therapies and systemic therapy in treating GIST when it metastasizes in the liver.
Dr. Suzanne George of the Dana-Farber Cancer Institute will review emerging data from the first-in-human StrateGIST 1 trial of IDRX-42 in patients with advanced GIST.